In what is believed to be the most comprehensive analysis of adenosquamous cancer of the pancreas (ASCP), the Mayo Clinic and TGen team identified, in preclinical models, therapeutic targets for this extremely fast-moving and deadly form of pancreatic cancer, and identified already available cancer inhibitors originally designed for other types of cancer, according to a study published today in Cancer Research, a journal of the American Association for Cancer Research (AACR). Read more . . .
A team of researchers led by Mayo Clinic and the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, has identified specific potential therapeutic targets for the most aggressive and lethal form of pancreatic cancer.